Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases? (Q38235580)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079039%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

title

Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079039%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

0 references

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079039%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

author name string

Kalliopi Pafili

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079039%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

Nikolaos Papanas

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079039%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

language of work or name

English

0 references

publication date

31 July 2014

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079039%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

11 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079039%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

volume

23

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079039%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

issue

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079039%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

page(s)

1277-1284

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079039%20AND%20SRC:MED&resulttype=core&format=json

Detailed mechanistic analysis of gevokizumab, an allosteric anti-IL-1β antibody with differential receptor-modulating properties

11 March 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

The role of interleukin-1 in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

The IL-1 family: regulators of immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Pro-interleukin (IL)-1beta shares a core region of stability as compared with mature IL-1beta while maintaining a distinctly different configurational landscape: a comparative hydrogen/deuterium exchange mass spectrometry study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Anti-inflammatory Agents: Present and Future

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Antibodies to watch in 2013: Mid-year update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Localization of type 1 diabetes susceptibility to the MHC class I genes HLA-B and HLA-A

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Prediction and pathogenesis in type 1 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

An update on preventive and regenerative therapies in diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Type 1 diabetes: new perspectives on disease pathogenesis and treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Blockade of interleukin 1 in type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Serum IL-1beta, IL-2, and IL-6 in insulin-dependent diabetic children

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Interleukin-1 stimulates beta-cell necrosis and release of the immunological adjuvant HMGB1

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Type 2 diabetes as an inflammatory disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Sensing pathogens and danger signals by the inflammasome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Cytokine production by islets in health and diabetes: cellular origin, regulation and function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Inhibitory effects of interleukin 1 on insulin secretion, insulin biosynthesis, and oxidative metabolism of isolated rat pancreatic islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Interleukin 1 dose-dependently affects the biosynthesis of (pro)insulin in isolated rat islets of Langerhans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Mouse islet cell lysis mediated by interleukin-1-induced Fas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Glucose promotes the production of interleukine-1beta and cyclooxygenase-2 in mesangial cells via enhanced (Pro)renin receptor expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Delay of type I diabetes in high risk, first degree relatives by parenteral antigen administration: the Schwabing Insulin Prophylaxis Pilot Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Inhibition of interleukin-1 responsiveness by type II receptor gene transfer: a surface "receptor" with anti-interleukin-1 function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

In vivo regulation of interleukin 1beta in patients with cryopyrin-associated periodic syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Interleukin-1-receptor antagonist in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Interleukin-1 receptor signaling rather than that of tumor necrosis factor is critical in protecting the host from the severe consequences of a polymicrobe anaerobic infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen Candida albicans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

One target-two different binding modes: structural insights into gevokizumab and canakinumab interactions to interleukin-1β

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

XOMA 052, a potent, high-affinity monoclonal antibody for the treatment of IL-1β-mediated diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1beta

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

A mutational analysis of receptor binding sites of interleukin-1 beta: differences in binding of human interleukin-1 beta muteins to human and mouse receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Kinetic approach to pathway attenuation using XOMA 052, a regulatory therapeutic antibody that modulates interleukin-1beta activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

XOMA 052, an anti-IL-1{beta} monoclonal antibody, improves glucose control and {beta}-cell function in the diet-induced obesity mouse model

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Increased secretion and expression of myostatin in skeletal muscle from extremely obese women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Dysregulated Toll-like receptor-induced interleukin-1β and interleukin-6 responses in subjects at risk for the development of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Molecular and biological actions of cyclosporin A and FK506 on T cell development and function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Metabolic and immunological effects of cyclosporin in recently diagnosed type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Cyclosporin and methotrexate therapy induces remission in type 1 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

The Pittsburgh insulin-dependent diabetes mellitus (IDDM) morbidity and mortality study. Mortality results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Short-term IL-1β blockade reduces monocyte CD11b integrin expression in an IL-8 dependent fashion in patients with type 1 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Gene Expression in Peripheral Blood Mononuclear Cells from Children with Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Combination Therapy with Cyclosporine and Methotrexate in Severe Rheumatoid Arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

Minutes of The 43rd General Assembly of The European Association for The Study of Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.2014.947026

10.1517/13543784.2014.947026

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25079039%20AND%20SRC:MED&resulttype=core&format=json

11 March 2020

1 reference